AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Signal transducer CD24

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P25063

UPID:

CD24_HUMAN

Alternative names:

Small cell lung carcinoma cluster 4 antigen

Alternative UPACC:

P25063; A0A087WYI6; B6EC88; Q16257; Q53XS0; R4I4T5

Background:

Signal transducer CD24, also known as Small cell lung carcinoma cluster 4 antigen, plays a crucial role in cell differentiation and immune response modulation. Its interaction with lectin-like ligands and subsequent signaling through GPI-anchor derived second messengers, significantly influences B-cell activation, proliferation, and the suppression of immune responses to danger-associated molecular patterns (DAMPs) such as HMGB1, HSP70, and HSP90.

Therapeutic significance:

Given its involvement in autoimmune diseases like Multiple sclerosis, where it is implicated in the autoimmune attack on the myelin sheath, understanding the role of CD24 could unveil novel therapeutic strategies aimed at modulating immune responses and promoting myelin sheath repair.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.